What is it about?
The aims of this study were to look at whether disease activity in children with juvenile idiopathic arthritis improved after one year of treatment with etanercept, and if so, which patients were more likely to do better. This analysis included children with JIA starting etanercept in the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. A total of 496 children were included. After 1 year, half of the patients had minimal disease symptoms. Patients were more likely to responder better to treatment if the were younger, had shorter disease duration, were not on steroids (likely because they had less severe disease), and a history of uveitis (likely because they started treatment due to uveitis not severe arthritis symptoms).
Featured Image
Why is it important?
In this real-world cohort of patients from the United Kingdom with severe JIA, a significant proportion of children achieved an excellent within 1 year of starting etanercept treatment. This is important information for patients starting this treatment to be aware of.
Perspectives
This was my second publication for the BSPAR Enbrel cohort study. I enjoyed looking at how children responded on treatment. It has been presented at one international and two national conferences.
Dr. Lianne Kearsley-Fleet
University of Manchester
Read the Original
This page is a summary of: Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study, Rheumatology, December 2015, Oxford University Press (OUP),
DOI: 10.1093/rheumatology/kev434.
You can read the full text:
Resources
Contributors
The following have contributed to this page
